Literature DB >> 23395906

A new genome-driven integrated classification of breast cancer and its implications.

Sarah-Jane Dawson1, Oscar M Rueda, Samuel Aparicio, Carlos Caldas.   

Abstract

Breast cancer is a group of heterogeneous diseases that show substantial variation in their molecular and clinical characteristics. This heterogeneity poses significant challenges not only in breast cancer management, but also in studying the biology of the disease. Recently, rapid progress has been made in understanding the genomic diversity of breast cancer. These advances led to the characterisation of a new genome-driven integrated classification of breast cancer, which substantially refines the existing classification systems currently used. The novel classification integrates molecular information on the genomic and transcriptomic landscapes of breast cancer to define 10 integrative clusters, each associated with distinct clinical outcomes and providing new insights into the underlying biology and potential molecular drivers. These findings have profound implications both for the individualisation of treatment approaches, bringing us a step closer to the realisation of personalised cancer management in breast cancer, but also provide a new framework for studying the underlying biology of each novel subtype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23395906      PMCID: PMC3590990          DOI: 10.1038/emboj.2013.19

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  65 in total

Review 1.  Pathological prognostic factors in breast cancer.

Authors:  C W Elston; I O Ellis; S E Pinder
Journal:  Crit Rev Oncol Hematol       Date:  1999-08       Impact factor: 6.312

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.

Authors:  Dmitry V Bulavin; Oleg N Demidov; Shin'ichi Saito; Paivikki Kauraniemi; Crissy Phillips; Sally A Amundson; Concetta Ambrosino; Guido Sauter; Angel R Nebreda; Carl W Anderson; Anne Kallioniemi; Albert J Fornace; Ettore Appella
Journal:  Nat Genet       Date:  2002-05-20       Impact factor: 38.330

6.  A gene-expression signature as a predictor of survival in breast cancer.

Authors:  Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

7.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.

Authors:  Diane C Fingar; Sofie Salama; Christina Tsou; Ed Harlow; John Blenis
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

8.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Authors:  Gottfried Konecny; Giovanni Pauletti; Mark Pegram; Michael Untch; Sugandha Dandekar; Zuleima Aguilar; Cindy Wilson; Hong-Mei Rong; Ingo Bauerfeind; Margret Felber; He-Jing Wang; Malgorzata Beryt; Ram Seshadri; Herrmann Hepp; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

9.  Molecular classification of breast carcinomas using tissue microarrays.

Authors:  Grace Callagy; Elena Cattaneo; Yataro Daigo; Lisa Happerfield; Lynda G Bobrow; Paul D P Pharoah; Carlos Caldas
Journal:  Diagn Mol Pathol       Date:  2003-03

10.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

Authors:  Suet F Chin; Andrew E Teschendorff; John C Marioni; Yanzhong Wang; Nuno L Barbosa-Morais; Natalie P Thorne; Jose L Costa; Sarah E Pinder; Mark A van de Wiel; Andrew R Green; Ian O Ellis; Peggy L Porter; Simon Tavaré; James D Brenton; Bauke Ylstra; Carlos Caldas
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  127 in total

1.  Keratin 19 expression correlates with poor prognosis in breast cancer.

Authors:  Nuzhat N Kabir; Lars Rönnstrand; Julhash U Kazi
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

2.  [Personalized urooncology based on molecular uropathology: what is the future?].

Authors:  E Dahl; F Haller
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

3.  Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.

Authors:  Matthew D Dun; Robert J Chalkley; Sam Faulkner; Sheridan Keene; Kelly A Avery-Kiejda; Rodney J Scott; Lasse G Falkenby; Murray J Cairns; Martin R Larsen; Ralph A Bradshaw; Hubert Hondermarck
Journal:  Mol Cell Proteomics       Date:  2015-06-03       Impact factor: 5.911

4.  Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy.

Authors:  Sandro Santagata; Tan A Ince
Journal:  Expert Rev Anticancer Ther       Date:  2014-09-27       Impact factor: 4.512

5.  Proteogenomics: emergence and promise.

Authors:  Sam Faulkner; Matthew D Dun; Hubert Hondermarck
Journal:  Cell Mol Life Sci       Date:  2015-01-22       Impact factor: 9.261

6.  The tubulysin analogue KEMTUB10 induces apoptosis in breast cancer cells via p53, Bim and Bcl-2.

Authors:  Oluwafunmilayo F Lamidi; Monica Sani; Paolo Lazzari; Matteo Zanda; Ian N Fleming
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-30       Impact factor: 4.553

Review 7.  High-throughput gene expression and mutation profiling: current methods and future perspectives.

Authors:  Thomas Karn
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

8.  Taxonomy of breast cancer based on normal cell phenotype predicts outcome.

Authors:  Sandro Santagata; Ankita Thakkar; Ayse Ergonul; Bin Wang; Terri Woo; Rong Hu; J Chuck Harrell; George McNamara; Matthew Schwede; Aedin C Culhane; David Kindelberger; Scott Rodig; Andrea Richardson; Stuart J Schnitt; Rulla M Tamimi; Tan A Ince
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

9.  Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing.

Authors:  Milan Radovich; Susan E Clare; Rutuja Atale; Ivanesa Pardo; Bradley A Hancock; Jeffrey P Solzak; Nawal Kassem; Theresa Mathieson; Anna Maria V Storniolo; Connie Rufenbarger; Heather A Lillemoe; Rachel J Blosser; Mi Ran Choi; Candice A Sauder; Diane Doxey; Jill E Henry; Eric E Hilligoss; Onur Sakarya; Fiona C Hyland; Matthew Hickenbotham; Jin Zhu; Jarret Glasscock; Sunil Badve; Mircea Ivan; Yunlong Liu; George W Sledge; Bryan P Schneider
Journal:  Breast Cancer Res Treat       Date:  2013-11-29       Impact factor: 4.872

10.  Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.

Authors:  K L Thu; J Silvester; M J Elliott; W Ba-Alawi; M H Duncan; A C Elia; A S Mer; P Smirnov; Z Safikhani; B Haibe-Kains; T W Mak; D W Cescon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.